Redirecting immune, lipid, and metabolic drivers of early cardiovascular disease: the RESET cohort study and randomized trial
- PMID: 37675563
- DOI: 10.1093/eurheartj/ehad543
Redirecting immune, lipid, and metabolic drivers of early cardiovascular disease: the RESET cohort study and randomized trial
Similar articles
-
Patient Engagement With a Game-Based Digital Therapeutic for the Treatment of Opioid Use Disorder: Protocol for a Randomized Controlled Open-Label, Decentralized Trial.JMIR Res Protoc. 2022 Jan 26;11(1):e32759. doi: 10.2196/32759. JMIR Res Protoc. 2022. PMID: 35080499 Free PMC article.
-
Occupational health disparities among U.S. long-haul truck drivers: the influence of work organization and sleep on cardiovascular and metabolic disease risk.PLoS One. 2018 Nov 15;13(11):e0207322. doi: 10.1371/journal.pone.0207322. eCollection 2018. PLoS One. 2018. PMID: 30439996 Free PMC article. Clinical Trial.
-
A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial.BMC Cancer. 2009 Dec 2;9:419. doi: 10.1186/1471-2407-9-419. BMC Cancer. 2009. PMID: 19951446 Free PMC article. Clinical Trial.
-
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.Am J Cardiovasc Drugs. 2005;5(6):379-87. doi: 10.2165/00129784-200505060-00005. Am J Cardiovasc Drugs. 2005. PMID: 16259526 Review.
-
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.Drugs. 2007;67 Suppl 1:43-54. doi: 10.2165/00003495-200767001-00005. Drugs. 2007. PMID: 17910520 Review.
Cited by
-
Primary Prevention of Cardiovascular Disease in Asia: Opportunities and Solutions: A Narrative Review.JACC Adv. 2025 Apr;4(4):101676. doi: 10.1016/j.jacadv.2025.101676. Epub 2025 Mar 22. JACC Adv. 2025. PMID: 40120215 Free PMC article.
Grants and funding
LinkOut - more resources
Full Text Sources